Sorafenib has been evaluated in several Phase II and III studies in patients with locally
advanced/metastatic radioactive iodine–refractory differentiated thyroid carcinomas (DTCs) …

Purpose Given the molecular pathophysiology of thyroid cancer and the spectrum of kinases
inhibited by sorafenib, including Raf kinase, vascular endothelial growth factor receptors …

Objective We conducted a prospective phase II clinical trial to determine the efficacy of
sorafenib in patients with advanced radio-iodine refractory differentiated thyroid cancer. In …

Sorafenib (Nexavar®) is the first tyrosine kinase inhibitor to be approved for the treatment of
radioactive iodine (RAI)-refractory differentiated thyroid carcinoma (DTC). In the pivotal …

Aim To evaluate the tolerability and efficacy of sorafenib in patients with thyroid carcinoma.
Methods Patients with progressive locally advanced/metastatic medullary thyroid carcinoma …

Sorafenib (Nexavar), is a multikinase inhibitor, which has demonstrated both anti
proliferative and anti-angiogenic properties in vitro and in vivo, inhibiting the activity of …

Introduction: Sorafenib (Nexavar) is an oral multi-kinase inhibitor targeting B-type Raf kinase
(BRAF)(both wild type and BRAFV600E), VEGFR1, VEGFR2, VEGFR3, PDGFRβ and RET …

Background: Sorafenib (BAY 43-9006) is an inhibitor of multiple-receptor tyrosine kinases
involved in tumor growth and angiogenesis, which can be advantageously administered …

The advent of biologically targeted agents and increased understanding of thyroid
carcinogenesis have generated much interest in the development of biologically targeted …

Background Patients with radioactive iodine (131 I)-refractory locally advanced or metastatic
differentiated thyroid cancer have a poor prognosis because of the absence of effective …